Salveen Richter
Stock Analyst at Goldman Sachs
(3.24)
# 1,190
Out of 4,412 analysts
130
Total ratings
41.24%
Success rate
2.76%
Average return
Main Sectors:
43 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Neutral | $28 → $19 | $13.69 | +38.79% | 6 | Apr 26, 2024 | |
| QURE uniQure | Downgrades: Neutral | $63 → $8 | $4.53 | +76.60% | 4 | Feb 29, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $73 → $50 | $15.43 | +224.04% | 4 | Feb 29, 2024 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $32 | $20.76 | +54.14% | 5 | Feb 23, 2024 | |
| ADPT Adaptive Biotechnologies | Maintains: Neutral | $11 → $5 | $2.60 | +92.31% | 3 | Feb 16, 2024 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Neutral | $230 → $173 | $143.31 | +20.72% | 3 | Feb 16, 2024 | |
| AMGN Amgen | Maintains: Buy | $313 → $350 | $269.98 | +29.64% | 3 | Feb 8, 2024 | |
| FDMT 4D Molecular Therapeutics | Reinstates: Buy | $81 | $23.25 | +248.39% | 3 | Feb 7, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $442 → $559 | $397.48 | +40.64% | 3 | Jan 31, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $65 → $90 | $49.86 | +80.51% | 2 | Jan 9, 2024 | |
| INCY Incyte | Maintains: Neutral | $98 → $65 | $51.68 | +25.77% | 4 | Nov 22, 2023 | |
| MRNA Moderna | Maintains: Buy | $269 → $231 | $107.97 | +113.95% | 5 | Nov 3, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Sell | $25 → $28 | $41.59 | -32.68% | 2 | Nov 3, 2023 | |
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $32 → $28 | $31.49 | -11.08% | 5 | Nov 3, 2023 | |
| TSVT 2seventy bio | Downgrades: Neutral | $5 | $4.26 | +17.51% | 4 | Sep 13, 2023 | |
| CNTA Centessa Pharmaceuticals | Maintains: Neutral | $4.5 → $5 | $8.92 | -43.95% | 5 | Aug 15, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $188 → $215 | $128.77 | +66.96% | 3 | Jun 23, 2023 | |
| FOLD Amicus Therapeutics | Maintains: Neutral | $10 → $11 | $10.28 | +7.00% | 1 | Mar 2, 2023 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $35 → $31 | $2.89 | +972.66% | 6 | Mar 2, 2023 | |
| ADSK Autodesk | Maintains: Overweight | $257 → $225 | $217.93 | +3.24% | 1 | Feb 24, 2023 | |
| PRME Prime Medicine | Initiates: Neutral | $22 | $4.43 | +397.18% | 1 | Nov 14, 2022 | |
| LYEL Lyell Immunopharma | Downgrades: Neutral | n/a | $2.17 | - | 4 | Nov 11, 2022 | |
| DTIL Precision BioSciences | Maintains: Neutral | $60 → $30 | $9.38 | +219.83% | 5 | Nov 10, 2022 | |
| KRON Kronos Bio | Maintains: Buy | $25 → $14 | $1.00 | +1,300.00% | 3 | Nov 10, 2022 | |
| RXRX Recursion Pharmaceuticals | Maintains: Neutral | $8 → $9 | $8.12 | +10.84% | 6 | Nov 9, 2022 | |
| TSHA Taysha Gene Therapies | Downgrades: Neutral | $16 → $3 | $2.39 | +25.52% | 4 | Nov 9, 2022 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Neutral | $74 → $55 | $44.24 | +24.32% | 1 | Nov 4, 2022 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Sell | $15 → $12 | $16.71 | -28.19% | 7 | Nov 4, 2022 | |
| SANA Sana Biotechnology | Maintains: Neutral | $7 → $6 | $8.72 | -31.19% | 2 | Nov 3, 2022 | |
| BFH Bread Financial Holdings | Maintains: Neutral | $39 → $43 | $36.97 | +16.31% | 1 | Oct 28, 2022 | |
| BIIB Biogen | Upgrades: Buy | $370 | $208.90 | +77.12% | 2 | Oct 26, 2022 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $796 → $970 | $883.20 | +9.83% | 2 | Oct 3, 2022 | |
| BLUE bluebird bio | Maintains: Sell | $2 → $3 | $0.92 | +225.10% | 4 | Aug 19, 2022 | |
| RLAY Relay Therapeutics | Maintains: Buy | $49 → $42 | $6.37 | +559.34% | 1 | May 24, 2022 | |
| OMGA Omega Therapeutics | Maintains: Neutral | $7 → $4 | $2.27 | +76.21% | 2 | May 24, 2022 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $46 | $53.91 | -14.67% | 2 | May 24, 2022 | |
| CLLS Cellectis | Maintains: Sell | $3 → $2 | $2.51 | -20.18% | 2 | May 24, 2022 | |
| ATRA Atara Biotherapeutics | Maintains: Sell | $5 → $4 | $0.69 | +479.71% | 1 | May 24, 2022 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $48 → $28 | $15.55 | +80.06% | 2 | May 12, 2022 | |
| GILD Gilead Sciences | Initiates: Neutral | n/a | $65.42 | - | 1 | Dec 6, 2021 | |
| PASG Passage Bio | Upgrades: Buy | n/a | $1.32 | - | 3 | Mar 4, 2021 | |
| PCAR PACCAR | Maintains: Neutral | n/a | $111.96 | - | 1 | Mar 19, 2020 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Neutral | n/a | $22.12 | - | 1 | Mar 17, 2020 |
Sage Therapeutics
Apr 26, 2024
Maintains: Neutral
Price Target: $28 → $19
Current: $13.69
Upside: +38.79%
uniQure
Feb 29, 2024
Downgrades: Neutral
Price Target: $63 → $8
Current: $4.53
Upside: +76.60%
Denali Therapeutics
Feb 29, 2024
Maintains: Buy
Price Target: $73 → $50
Current: $15.43
Upside: +224.04%
Intellia Therapeutics
Feb 23, 2024
Downgrades: Neutral
Price Target: $32
Current: $20.76
Upside: +54.14%
Adaptive Biotechnologies
Feb 16, 2024
Maintains: Neutral
Price Target: $11 → $5
Current: $2.60
Upside: +92.31%
Alnylam Pharmaceuticals
Feb 16, 2024
Downgrades: Neutral
Price Target: $230 → $173
Current: $143.31
Upside: +20.72%
Amgen
Feb 8, 2024
Maintains: Buy
Price Target: $313 → $350
Current: $269.98
Upside: +29.64%
4D Molecular Therapeutics
Feb 7, 2024
Reinstates: Buy
Price Target: $81
Current: $23.25
Upside: +248.39%
Vertex Pharmaceuticals
Jan 31, 2024
Maintains: Buy
Price Target: $442 → $559
Current: $397.48
Upside: +40.64%
Apellis Pharmaceuticals
Jan 9, 2024
Maintains: Buy
Price Target: $65 → $90
Current: $49.86
Upside: +80.51%
Incyte
Nov 22, 2023
Maintains: Neutral
Price Target: $98 → $65
Current: $51.68
Upside: +25.77%
Moderna
Nov 3, 2023
Maintains: Buy
Price Target: $269 → $231
Current: $107.97
Upside: +113.95%
Ionis Pharmaceuticals
Nov 3, 2023
Maintains: Sell
Price Target: $25 → $28
Current: $41.59
Upside: -32.68%
Agios Pharmaceuticals
Nov 3, 2023
Maintains: Neutral
Price Target: $32 → $28
Current: $31.49
Upside: -11.08%
2seventy bio
Sep 13, 2023
Downgrades: Neutral
Price Target: $5
Current: $4.26
Upside: +17.51%
Centessa Pharmaceuticals
Aug 15, 2023
Maintains: Neutral
Price Target: $4.5 → $5
Current: $8.92
Upside: -43.95%
Sarepta Therapeutics
Jun 23, 2023
Maintains: Buy
Price Target: $188 → $215
Current: $128.77
Upside: +66.96%
Amicus Therapeutics
Mar 2, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $10.28
Upside: +7.00%
Allogene Therapeutics
Mar 2, 2023
Maintains: Buy
Price Target: $35 → $31
Current: $2.89
Upside: +972.66%
Autodesk
Feb 24, 2023
Maintains: Overweight
Price Target: $257 → $225
Current: $217.93
Upside: +3.24%
Prime Medicine
Nov 14, 2022
Initiates: Neutral
Price Target: $22
Current: $4.43
Upside: +397.18%
Lyell Immunopharma
Nov 11, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.17
Upside: -
Precision BioSciences
Nov 10, 2022
Maintains: Neutral
Price Target: $60 → $30
Current: $9.38
Upside: +219.83%
Kronos Bio
Nov 10, 2022
Maintains: Buy
Price Target: $25 → $14
Current: $1.00
Upside: +1,300.00%
Recursion Pharmaceuticals
Nov 9, 2022
Maintains: Neutral
Price Target: $8 → $9
Current: $8.12
Upside: +10.84%
Taysha Gene Therapies
Nov 9, 2022
Downgrades: Neutral
Price Target: $16 → $3
Current: $2.39
Upside: +25.52%
Ultragenyx Pharmaceutical
Nov 4, 2022
Maintains: Neutral
Price Target: $74 → $55
Current: $44.24
Upside: +24.32%
ACADIA Pharmaceuticals
Nov 4, 2022
Downgrades: Sell
Price Target: $15 → $12
Current: $16.71
Upside: -28.19%
Sana Biotechnology
Nov 3, 2022
Maintains: Neutral
Price Target: $7 → $6
Current: $8.72
Upside: -31.19%
Bread Financial Holdings
Oct 28, 2022
Maintains: Neutral
Price Target: $39 → $43
Current: $36.97
Upside: +16.31%
Biogen
Oct 26, 2022
Upgrades: Buy
Price Target: $370
Current: $208.90
Upside: +77.12%
Regeneron Pharmaceuticals
Oct 3, 2022
Maintains: Buy
Price Target: $796 → $970
Current: $883.20
Upside: +9.83%
bluebird bio
Aug 19, 2022
Maintains: Sell
Price Target: $2 → $3
Current: $0.92
Upside: +225.10%
Relay Therapeutics
May 24, 2022
Maintains: Buy
Price Target: $49 → $42
Current: $6.37
Upside: +559.34%
Omega Therapeutics
May 24, 2022
Maintains: Neutral
Price Target: $7 → $4
Current: $2.27
Upside: +76.21%
CRISPR Therapeutics AG
May 24, 2022
Maintains: Neutral
Price Target: $52 → $46
Current: $53.91
Upside: -14.67%
Cellectis
May 24, 2022
Maintains: Sell
Price Target: $3 → $2
Current: $2.51
Upside: -20.18%
Atara Biotherapeutics
May 24, 2022
Maintains: Sell
Price Target: $5 → $4
Current: $0.69
Upside: +479.71%
Arcus Biosciences
May 12, 2022
Maintains: Neutral
Price Target: $48 → $28
Current: $15.55
Upside: +80.06%
Gilead Sciences
Dec 6, 2021
Initiates: Neutral
Price Target: n/a
Current: $65.42
Upside: -
Passage Bio
Mar 4, 2021
Upgrades: Buy
Price Target: n/a
Current: $1.32
Upside: -
PACCAR
Mar 19, 2020
Maintains: Neutral
Price Target: n/a
Current: $111.96
Upside: -
Arrowhead Pharmaceuticals
Mar 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $22.12
Upside: -